IDH1 and central nervous system cancer: The IDH1 mutation fundamentally impedes the generation of NADPH and α‐KG, compromising ROS‐scavenging capacity and ultimately leading to intracellular hydrogen peroxide (H2O2) accumulation.[13] Consequently, gliomas harboring IDH1‐MUT exhibit higher H2O2 levels than IDH1‐WT counterparts, making H2O2 a potential diagnostic biomarker for detecting IDH1 mutations.[14] Meanwhile, the intracellular GSH is reduced by the consumption of excess ROS in IDH1‐MUT glioma.